Patents Examined by Amanda Haney
  • Patent number: 10550434
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: February 4, 2020
    Assignee: Celera Corporation
    Inventors: Olga Iakoubova, James J. Devlin
  • Patent number: 10544462
    Abstract: The present invention relates generally to the identification of subjects with a predisposition to recurrent depression, predicting a subject's responsiveness to therapy, and determining whether a subject has remitted from depression following therapy. In particular, provided herein are biomarkers, methods, and kits for such uses.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 28, 2020
    Assignee: NORTHWESTERN UNIVERSITY
    Inventor: Eva E. Redei
  • Patent number: 10533226
    Abstract: The gene responsible for encoding SERT has a functional polymorphism at the 5?-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3? UTR SNP rs1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on variations in the polymorphisms of the SERT gene as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: January 14, 2020
    Assignee: University of Virginia Patent Foundation
    Inventor: Bankole A. Johnson
  • Patent number: 10501799
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 10, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Weimin Sun, Matthew J. McGinniss, Donghui Huang, Arlene Buller, Raymond Fenwick, Mei Peng, Franklin Quan
  • Patent number: 10465248
    Abstract: Provided herein is technology relating compositions and methods for detecting tissue cell-specific DNA, such as epithelial cell-specific DNA, in blood or blood products from a subject. The technology also relates to use of tissue cell-specific DNAs as internal controls for methylation assays.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: November 5, 2019
    Assignee: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
    Inventors: Hatim T. Allawi, Graham P. Lidgard
  • Patent number: 10465249
    Abstract: Provided herein is technology relating compositions and methods for detecting tissue cell-specific DNA in blood or blood products from a subject of a subject having cancer. The technology also relates to use of tissue cell-specific DNAs as internal controls for methylation assays.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: November 5, 2019
    Assignee: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
    Inventors: Hatim T. Allawi, Graham P. Lidgard
  • Patent number: 10457991
    Abstract: Provided herein are compositions, kits, and methods for the identification of depressive disorders. In particular, provided herein are compositions, kits, and methods for the detection or diagnosis of major depressive disorder.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: October 29, 2019
    Assignee: Northwestern University
    Inventor: Eva E. Redei
  • Patent number: 10450616
    Abstract: The invention provides methods and compositions for the detection of Chlamydia trachomatis in a test sample. Its presence or absence in the sample is determined by nucleic acid based testing methods using primers and/or probes and or molecular beacons that bind to the 23S ribosomal genes or gene transcripts.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: October 22, 2019
    Assignee: Talis Biomedical Corporation
    Inventors: Andrea Dedent, Matt Lee, Shuyuan Ma, Hédia Maamar
  • Patent number: 10443102
    Abstract: The invention relates generally to new prostate cancer markers, and particularly to a class of cancer marked by the presence of missense mutations in SPOP, an E3 ubiquitin ligase component. The invention provides methods and materials for detecting and diagnosing prostate cancer by detecting these mutations and may be useful in predicting disease progression and response to therapy.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: October 15, 2019
    Assignee: Cornell University
    Inventors: Mark A. Rubin, Christopher Barbieri
  • Patent number: 10428384
    Abstract: The present invention relates generally to the detection or diagnosis of post-traumatic stress states in a subject, and provides methods, reagents, and kits useful for this purpose. Provided herein are biomarkers that are indicative of and/or diagnostic of post-traumatic stress states including PTSD.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: October 1, 2019
    Assignee: Northwestern University
    Inventor: Eva E. Redei
  • Patent number: 10407726
    Abstract: Disclosed herein are miRNA biomarkers and methods for measuring exposure of a mammalian subject to ionizing radiation using a cell-free biological sample. Also disclosed are dosimeters and methods for triaging and treating a subject exposed to ionizing radiation.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 10, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Naduparambil Jacob, Arnab Chakravarti
  • Patent number: 10400282
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods for determining the ovarian reserve and ovarian function by determining the level of cell-free nucleic acids or the level of a miRNA species selected from miR_30_a or miR_140 or let_7_b or miR_191 or miR_320_a or miR_21 or miR_30_d or miR_574_3p. The method may also be used in predicting the efficacy of controlled ovarian hyperstimulation.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: September 3, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
    Inventors: Samir Hamamah, Sabine Traver, Elodie Scalici
  • Patent number: 10378056
    Abstract: The present invention provides a method of identifying a human subject as having an increased risk of altered effectiveness of beta blocker therapy, comprising detecting in the subject one or more single nucleotide polymorphism associated with increased risk of altered effectiveness of beta blocker therapy.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 13, 2019
    Assignee: Duke University
    Inventors: Miklos D. Kertai, Mihai V. Podgoreanu, Joseph P. Mathew, Yi-Ju Li
  • Patent number: 10378060
    Abstract: The present invention is based on the identification of novel biomarkers predictive of response to anti-cancer therapies.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: August 13, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Ronald A. DePinho, Ji-Hye Paik
  • Patent number: 10358640
    Abstract: A process for separating prokaryotic DNA from eukaryotic DNA in a whole blood sample infected by pathogen is provided. The process includes extracting prokaryotic and eukaryotic DNA from the whole blood sample, contacting the prokaryotic DNA in the whole blood sample with a motif that specifically binds to the prokaryotic DNA, and generating a bound pair. The process also includes separating the bound pair. The whole blood sample is transfected with bacteriophages genetically modified to contain a defined DNA sequence having a selectable marker DNA. The DNA sequence integrates into the prokaryotic DNA, and the motif is an oligonucleotide specific to the defined DNA sequence in the engineered bacteriophages.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: July 23, 2019
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Subhadra Rukmini Jayaraman, Ramya Vutukuru
  • Patent number: 10322127
    Abstract: Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: June 18, 2019
    Assignee: The Translational Genomics Research Institute
    Inventors: Haiyong Han, Daniel Von Hoff, Caroline H. Diep, Hongwei Yin
  • Patent number: 10308980
    Abstract: The present invention relates to methods and biomarkers (e.g., gene expression biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer and in providing a prognosis to colorectal cancer patients.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: June 4, 2019
    Assignee: OSLO UNIVERSITETSSYKEHUS HF
    Inventors: Ragnhild A. Lothe, Trude Holmeide Agesen, Anita Sveen, Guro Elisabeth Lind, Arild Nesbakken, Rolf Inge Skotheim
  • Patent number: 10294530
    Abstract: The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the FOXF2 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing FOXF2 gene expression or activity.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 21, 2019
    Assignee: The Chinese University of Hong Kong
    Inventors: Jun Yu, Joseph Jao Yiu Sung
  • Patent number: 10280472
    Abstract: Methods for obtaining genetic material from plant embryos while preserving their viability as well as methods for performing a molecular analysis of plant embryos, particularly with small quantities of genetic material by collecting shed cellular material from one or more plant embryos; obtaining DNA from the shed cellular material; performing a molecular analysis of the DNA; and germinating at least one of the one or more plant embryos. A further extension includes determining whether to germinate and grow the embryo or to discard the embryo based on its genotype as part of a breeding process. Also provided are methods of genotyping embryos using embryo shed cellular material contained in or on agar and methods of analyzing plant embryonic tissue derived from microspores.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: May 7, 2019
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Randal Arnold, Matthew Paul Cope, Justin Andrew Schares, Yue Yun
  • Patent number: 10260104
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 16, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker